HSV1716 (Seprehvir TM) in combination with TACE in patients with HCC

• Research type

  Research Study

• Full title

  A Phase I/IIA trial of the Safety, Tolerability and Efficacy of Intra-arterial Injection of the Selectively Replication-Competent Herpes Simplex Virus HSV1716 (also known as Seprehvir-Trade Mark) in Combination with TACE in Patients with Unresectable Hepatocellular Carcinoma

• IRAS ID

  129862

• Contact name

  Nagy Habib

• Contact email

  nagy.habib@imperial.ac.uk

• Eudract number

  2013-001927-38

• ISRCTN Number

  n.a

• REC name

  London - West London & GTAC Research Ethics Committee

• REC reference

  13/LO/0913

• Date of REC Opinion

  24 Sep 2013

• REC opinion

  Further Information Favourable Opinion